CA2001123A1 - Traitement de l'osteoporose - Google Patents

Traitement de l'osteoporose

Info

Publication number
CA2001123A1
CA2001123A1 CA2001123A CA2001123A CA2001123A1 CA 2001123 A1 CA2001123 A1 CA 2001123A1 CA 2001123 A CA2001123 A CA 2001123A CA 2001123 A CA2001123 A CA 2001123A CA 2001123 A1 CA2001123 A1 CA 2001123A1
Authority
CA
Canada
Prior art keywords
osteoporosis
treatment
preferred
potassium
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2001123A
Other languages
English (en)
Other versions
CA2001123C (fr
Inventor
R. Curtis Morris, Jr.
Anthony Sebastian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2001123A1 publication Critical patent/CA2001123A1/fr
Application granted granted Critical
Publication of CA2001123C publication Critical patent/CA2001123C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002001123A 1988-10-21 1989-10-20 Traitement de l'osteoporose Expired - Fee Related CA2001123C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26085688A 1988-10-21 1988-10-21
US260,856 1988-10-21

Publications (2)

Publication Number Publication Date
CA2001123A1 true CA2001123A1 (fr) 1990-04-21
CA2001123C CA2001123C (fr) 2000-01-18

Family

ID=22990921

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002001123A Expired - Fee Related CA2001123C (fr) 1988-10-21 1989-10-20 Traitement de l'osteoporose
CA002001124A Expired - Fee Related CA2001124C (fr) 1988-10-21 1989-10-20 Traitement de l'hypertension

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002001124A Expired - Fee Related CA2001124C (fr) 1988-10-21 1989-10-20 Traitement de l'hypertension

Country Status (13)

Country Link
US (1) US5804204A (fr)
EP (3) EP0461111B1 (fr)
JP (2) JP2843146B2 (fr)
KR (2) KR0163583B1 (fr)
AT (1) ATE145825T1 (fr)
AU (2) AU635231B2 (fr)
CA (2) CA2001123C (fr)
DE (2) DE68927519T2 (fr)
DK (2) DK175841B1 (fr)
HU (2) HU212106B (fr)
IL (2) IL92076A (fr)
WO (2) WO1990004403A1 (fr)
ZA (2) ZA898018B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
CA2480882A1 (fr) * 2002-04-05 2003-10-23 Btg International Limited Apport complementaire en potassium a faible dose pour la prevention et le traitement de l'hypertension
EP1350515A1 (fr) * 2002-04-05 2003-10-08 Btg International Limited Supplément de potassium à faible dose pour la prévention et la thérapie de l'hypertension
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US10251909B2 (en) * 2007-02-09 2019-04-09 Board Of Regents, The University Of Texas System Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
US20090022853A1 (en) * 2007-07-16 2009-01-22 Conopco, Inc., D/B/A Unilever Beverage
WO2009099466A1 (fr) * 2008-02-06 2009-08-13 Campbell Soup Company Procédés et compositions pour réduire la teneur en sodium de produits alimentaires
EP2320753B1 (fr) * 2008-09-05 2011-12-21 Unilever N.V. Boissons comprenant du potassium
US20230372389A1 (en) * 2020-10-09 2023-11-23 Zhi Liu Inhalation formulation, and preparation method therefor and application thereof
CN114272263A (zh) * 2022-01-10 2022-04-05 伍永田 一种用于治疗高血压疾病的水配方
CN116819083B (zh) * 2023-06-20 2025-05-27 齐鲁工业大学(山东省科学院) 一种基于重组人肾素分子印迹聚合物的电化学生物传感器、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
GB1195381A (en) * 1967-04-28 1970-06-17 Arthur H Cox & Company Ltd Pharmaceutical Compositions Comprising Potassium and Chlorine
US3639585A (en) * 1968-03-29 1972-02-01 Res Inst Medicine Chem Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method
US3541208A (en) * 1968-09-10 1970-11-17 Arcom Holding Corp Relief of arthritis with a soluble silicate and a soluble polyphosphate
US3921804A (en) * 1974-05-09 1975-11-25 William W Tester Medication dispensing package
SU858830A1 (ru) * 1974-10-23 1981-08-30 Институт медико-биологических проблем Средство дл лечени нарушений ритма сердца
SU946545A1 (ru) * 1978-05-04 1982-07-30 Институт Медико-Биологических Проблем Министерства Здравоохранения Ссср Способ восполнени калиевого дефицита в ткан х
FR2432869A1 (fr) * 1978-08-08 1980-03-07 Armour Montagu Laboratoire Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
US4405596A (en) * 1978-10-16 1983-09-20 Helbig Joachim W Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
US4704269A (en) * 1985-06-11 1987-11-03 Hudson Pharmaceutical Corporation Effervescent antacid and analgesic compositions
JPH0619063B2 (ja) * 1986-04-09 1994-03-16 日本エステル株式会社 粉体塗料用樹脂組成物

Also Published As

Publication number Publication date
JPH04501419A (ja) 1992-03-12
AU634988B2 (en) 1993-03-11
IL92075A (en) 1995-07-31
JP2948247B2 (ja) 1999-09-13
AU635231B2 (en) 1993-03-18
EP0440738A4 (en) 1991-08-28
EP0461111B1 (fr) 1994-02-23
DK175841B1 (da) 2005-03-29
JPH04501724A (ja) 1992-03-26
IL92075A0 (en) 1990-07-12
CA2001123C (fr) 2000-01-18
DE68913311T2 (de) 1994-05-26
IL92076A0 (en) 1990-07-12
HUT63058A (en) 1993-07-28
KR0178033B1 (ko) 1999-03-20
KR900701287A (ko) 1990-12-01
ZA898017B (en) 1990-12-28
HU896567D0 (en) 1991-07-29
HU896889D0 (en) 1991-07-29
EP0440738A1 (fr) 1991-08-14
KR900701288A (ko) 1990-12-01
WO1990004403A1 (fr) 1990-05-03
CA2001124A1 (fr) 1990-04-21
DK175840B1 (da) 2005-03-29
AU4622089A (en) 1990-05-14
DK72691D0 (da) 1991-04-19
HU212106B (en) 1996-02-28
HU208923B (en) 1994-02-28
ATE145825T1 (de) 1996-12-15
DK72791D0 (da) 1991-04-19
DE68927519D1 (de) 1997-01-16
DE68913311D1 (de) 1994-03-31
ZA898018B (en) 1990-12-28
CA2001124C (fr) 2000-01-18
IL92076A (en) 1995-08-31
EP0720855A3 (fr) 1998-07-08
DK72791A (da) 1991-05-14
WO1990004402A1 (fr) 1990-05-03
EP0720855A2 (fr) 1996-07-10
HUT57989A (en) 1992-01-28
KR0163583B1 (ko) 1998-12-01
DK72691A (da) 1991-04-22
EP0461111A4 (fr) 1991-07-25
EP0440738B1 (fr) 1996-12-04
AU4515489A (en) 1990-05-14
DE68927519T2 (de) 1997-04-03
US5804204A (en) 1998-09-08
JP2843146B2 (ja) 1999-01-06
EP0461111A1 (fr) 1991-12-18

Similar Documents

Publication Publication Date Title
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
JPS57193412A (en) Prevention of prostatic hyperplasia and therapeutical drug
ZA894128B (en) Use of gamma-hydroxybutryic acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism,and the compositions obtained
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
CA2001123A1 (fr) Traitement de l'osteoporose
AU4658489A (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma
CA2068069A1 (fr) Concentre de facteur xi intervenant dans la coagulation du sang presentant une activite specifique elevee, pouvant etre utilise a des fins therapeutiques, et procede pour le preparer
EP0344997A3 (fr) Utilisation de l'acide phytique ou d'un de ses sels comme activateur des cellules hypoxiques et comme améliorateur circulatoire
SE8803125L (sv) Orala magnesium- och kaliumkompositioner
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
IE840977L (en) Pharmaceutical preparations
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
IE782515L (en) Treating diarrhoea
SU1630043A1 (ru) Плазмозамещающий раствор для лечения шока "мафусол"
DE3879489D1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
ATE66150T1 (de) Pharmazeutische zubereitung fuer orale verabreichung von eisensalzen, verwendbar zur behandlung von anaemien durch eisenmangel.
IL82317A0 (en) 1,4 dihydropyridine derivatives,processes for their preparation and medicaments containing these compounds
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
RU92011330A (ru) Способ лечения диффузного зоба щитовидной железы
IT1239038B (it) Composizioni farmaceutiche e dietetiche a base di aspartati

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed